Bicycle Therapeutics Ltd

NASDAQ BCYC

Data sourced from

and

Download Data

Bicycle Therapeutics Ltd Interest Coverage Ratio 1 year YoY Change (%) for the year ending December 31, 2023: -54.05%

Bicycle Therapeutics Ltd Interest Coverage Ratio 1 year YoY Change (%) is -54.05% for the year ending December 31, 2023, a 7.82% change year over year. The interest coverage ratio is a measure of a company's ability to meet its interest payment obligations on its outstanding debt. It is calculated by dividing the company's earnings before interest and taxes (EBIT) by its interest expense. This ratio indicates the extent to which a company's earnings can cover its interest expenses. A higher interest coverage ratio suggests that the company has a greater capacity to make interest payments, indicating lower financial risk. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Bicycle Therapeutics Ltd Interest Coverage Ratio for the year ending December 31, 2022 was -34.88, a -58.64% change year over year.
Bicycle Therapeutics Ltd Interest Coverage Ratio for the year ending December 31, 2021 was -21.99, a 80.66% change year over year.
Bicycle Therapeutics Ltd Interest Coverage Ratio for the year ending December 31, 2020 was -113.70, a -1,402.82% change year over year.
Bicycle Therapeutics Ltd Interest Coverage Ratio for the year ending December 31, 2019 was -7.57.

NASDAQ: BCYC

Bicycle Therapeutics Ltd

CEO	Dr. Kevin Lee M.B.A., Ph.D.
IPO Date	May 23, 2019
Location	United Kingdom
Headquarters	Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT
Employees	284
Sector	Healthcare
Industry	Biotechnology

Description

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Key trends